Edgestream Partners, L.P. Acadia Pharmaceuticals Inc Transaction History
Edgestream Partners, L.P.
- $2.23 Billion
- Q3 2024
A detailed history of Edgestream Partners, L.P. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Edgestream Partners, L.P. holds 219,329 shares of ACAD stock, worth $3.57 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
219,329
Previous 90,957
141.13%
Holding current value
$3.57 Million
Previous $1.48 Million
128.35%
% of portfolio
0.15%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding ACAD
# of Institutions
280Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$698 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$225 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$223 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$97.2 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.63B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...